ChemVassa: A New Method for Identifying Small Molecule Hits in Drug Discovery

نویسندگان

  • Brian Moldover
  • Ada Solidar
  • Christa Montgomery
  • Henry Miziorko
  • Jeff Murphy
  • Gerald J. Wyckoff
چکیده

ChemVassa, a new chemical structure search technology, was developed to allow rapid in silico screening of compounds for hit and hit-to-lead identification in drug development. It functions by using a novel type of molecular descriptor that examines, in part, the structure of the small molecule undergoing analysis, yielding its "information signature." This descriptor takes into account the atoms, bonds, and their positions in 3-dimensional space. For the present study, a database of ChemVassa molecular descriptors was generated for nearly 16 million compounds (from the ZINC database and other compound sources), then an algorithm was developed that allows rapid similarity searching of the database using a query molecular descriptor (e.g., the signature of atorvastatin, below). A scoring metric then allowed ranking of the search results. We used these tools to search a subset of drug-like molecules using the signature of a commercially successful statin, atorvastatin (Lipitor™). The search identified ten novel compounds, two of which have been demonstrated to interact with HMG-CoA reductase, the macromolecular target of atorvastatin. In particular, one compound discussed in the results section tested successfully with an IC50 of less than 100uM and a completely novel structure relative to known inhibitors. Interactions were validated using computational molecular docking and an Hmg-CoA reductase activity assay. The rapidity and low cost of the methodology, and the novel structure of the interactors, suggests this is a highly favorable new method for hit generation.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Identification of novel Kv1.3 blockers using a fluorescent cell-based ion channel assay.

A functional cell-based assay was developed using a generic proprietary assay protocol, based on a membrane-potential sensitive dye, for the identification of small-molecule antagonists against the Kv1.3 potassium ion channel. A high-throughput screen (HTS) was subsequently performed with 20,000 compounds from the Evotec library, preselected using known small molecule antagonists for both sodiu...

متن کامل

Reverse Pharmacology: a New Approach to Drug Development

The pharmaceutical sector has traditionally been a vibrant, innovation-driven and highly successful component of global industry. A confluence of spectacular advances in chemistry, molecular biology, genomics and chemical technology and the cognate fields of spectroscopy, chromatography and crystallography led to the discovery and development of numerous novel therapeutic agents for the treatme...

متن کامل

Fragments and hot spots in drug discovery

Drug discovery requires finding a " plug " that fits extremely well and with high specificity into a functional site on a protein target. This difficult task often requires screening of very large compound libraries, and on occasion screening finds no useful compounds at all. For many years, a failed screening effort left unanswered whether this outcome resulted from the absence of suitable com...

متن کامل

A roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatment.

Drug discovery and development, from an initial disease treatment concept to a new drug application (NDA), is a complex, lengthy and expensive process. In this review we discuss the key stages of drug discovery and early development, including target identification and validation, assay development and screening, confirmed hits to leads, lead optimization, and progressing development candidates...

متن کامل

Designing small molecules to target cryptic pockets yields both positive and negative allosteric modulators

Allosteric drugs, which bind to proteins in regions other than their main ligand-binding or active sites, make it possible to target proteins considered "undruggable" and to develop new therapies that circumvent existing resistance. Despite growing interest in allosteric drug discovery, rational design is limited by a lack of sufficient structural information about alternative binding sites in ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 6  شماره 

صفحات  -

تاریخ انتشار 2012